AI-powered search

Connecting the Dots Between Prurigo Nodularis and Atopic Dermatitis With Biologics: An Online Activity

Section cover
Released on
March 28, 2025
Duration
50 minutes
Earn up to
0.75 AMA PRA Category 1 Credit

Connecting the Dots Between Prurigo Nodularis and Atopic Dermatitis With Biologics: An Online Activity

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals, Inc.

This symposium from the 2025 Winter Clinical Hawaii conference delves into type 2 inflammation as a driver of chronic itch in the neuroimmune axis, connecting two seemingly disparate diseases- atopic dermatitis and prurigo nodularis. Experts review how biologics targeted against type 2 cytokines can help patients with either condition achieve rapid, lasting symptom relief.

“We have drugs that will help us in atopic dermatitis, we have those that will help us in prurigo nodularis, and then we have some that we can really use either way. When we think about therapy, we’re really going to work on treating those key [type 2 inflammatory] cytokines. We’re really fortunate that now we have multiple therapies.”
-Dawn Merritt, DO